Accelerating Belgian health-tech & biopharma innovation

About BioWin
iStock-1093656424-web5

See what’s happening in Wallonia, Belgium

News

Learn more
getty-images-Y_aIhr_69hU-unsplash

BioWin launches call 47 for collaborative health innovation projects

    Funding Innovation

10.09.2025

Learn more
_MGL01134

PRESS RELEASE: Belgian health innovators set to meet on September 23 and 24, 2025 at BioWin Days

    Press release

28.08.2025

Learn more
fellipe-ditadi-3gE3f-LbEXw-unsplash-(1)

BioWin presents feasibility analysis report of a vaccine trial network at BioWin Days

Belgium has long been recognised as a global leader in vaccine trials, thanks to world-class expertise, strong centres of excellence and a highly integrated supply chain. Yet, this leadership is now under pressure. At the upcoming BioWin Days, BioWin will unveil the results of a feasibility analysis on a federal vaccine trial network. The study […]

    Vaccines

27.08.2025

Learn more

Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101

    Press release

11.09.2025

Learn more

One2Treat raises capital to further accelerate software platform development and relocates offices to support rapid growth

    Press release

08.09.2025

Learn more
220506-packshot-Kiomedine052022-ser-1536x813

KiOmed Pharma receives approval from the Chinese FDA for KioMedineVSone

    Press release

05.09.2025

Success stories

erik-karits-QKfx7ZWEEqE-unsplash
Drug development

How Bioxodes is rewriting the rules of haemorrhagic stroke treatment

Bioxodes develops Ir-CPI, a first-in-class drug to prevent thrombosis and neuroinflammation in haemorrhagic stroke patients.
02.07.2025
Next:

Fund Pivotal Phase 2b to gain marketing approval by 2030
iStock-1314783908-web
Nuclear Medecine

How ABSCINT is redefining cancer diagnostics

ABSCINT is a molecular imaging company. ABSCINT has two lead programs in clinical stage, one in cardiovascular disease and one in oncology.
20.06.2025
2028

ABSCINT to launch first diagnostics in EU & NA
trasis_2022_closeup_web-34_11
Nuclear Medecine

How Trasis turned teamwork into nuclear medicine innovation

Trasis develops and supplies integrated solutions for radiopharmaceutical production, helping research, industry & hospitals advance nuclear medicine worldwide.
27.05.2025
€72M

Record 2024 sales

Stay informed with the BioWin newsletter

Subscribe

Innovate

Why join BioWin

We help simplify the path to bringing innovative ideas to life. With nearly 20 years of hands-on collaborative innovation experience, we don’t just connect companies, research centers, hospitals, and academic institutions—we’re a true partner, offering real support at every step of the research and development process.

From shaping your project to sourcing its financing and ensuring it stays on track, that’s how we give health-tech and biopharma innovations their greatest chance of success.

Learn more
iStock-542576976

Connect

Why join BioWin

In a bid to increase opportunities for our members in terms of both collaboration and market expansion, we connect them to partners through regular events. We also seek to enhance sector attractiveness to source the future talent needed to create sustainable innovation across the Walloon Region.

 

Learn more
iStock-530685719

Communicate

Why join BioWin

Our targeted communication strategies aim to strengthen Wallonia’s profile, while maximising our members’ presence both locally and globally.

Learn more
getty-images-B1n_PGHf4JA-unsplash

Operating at the epicentre of regional health-tech & biopharma innovation

What we work on

Biopharma

iStock-1289345741

Health-tech

iStock-1125084447-web
  • From championing collaborative innovation to playing a more global role in the implementation of the sector’s industrial policy, making innovation happen is part of our DNA.
  • We aim to increase the competitiveness of the Walloon region in the biopharma and health-tech sectors by identifying and supporting strategic projects and portfolios for the benefit of our members and the patients they serve.
  • BioWin’s network of 260+ world-class organisations is an exceptional ecosystem known for both its academic excellence and robust industrial value chain in biomanufacturing, advanced therapies, nuclear medicine and medical technologies. 

Our ecosystem at a glance

Numbers

Our ecosystem

269

supported organisations

89

supported R&D projects

313,76M

€ raised by our members through public-private funding

6

job offers